Dr. Schroeder on Tolerability of Treatment For Myeloma

Mark Schroeder, MD
Published: Wednesday, Oct 24, 2018



Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.
 
When patients are treated with regimens that include pomalidomide (Pomalyst), they are typically at risk of developing neutropenia. This often leads to dose reduction—whether it is combining pomalidomide with bortezomib (Velcade) or pomalidomide with daratumumab (Darzalex) and dexamethasone. In general, Schroeder notes, these doublet and triplet regimens are manageable and patients can get through them without any major issues.
 
Infusion reactions to daratumumab-based regimens are possible, but with split dosing this is particularly avoidable. Infusion time is also lessened in that setting with proper pre-dosing. Because of the lack of single-agent activity with elotuzumab (Empliciti), Schroeder adds, there is still ongoing work testing it in combination with other agents.  
 
SELECTED
LANGUAGE


Mark Schroeder, MD, assistant professor of medicine, Division of Oncology, Section of Bone Marrow Transplantation and Leukemia, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the tolerability of treatment regimens for patients with relapsed/refractory myeloma.
 
When patients are treated with regimens that include pomalidomide (Pomalyst), they are typically at risk of developing neutropenia. This often leads to dose reduction—whether it is combining pomalidomide with bortezomib (Velcade) or pomalidomide with daratumumab (Darzalex) and dexamethasone. In general, Schroeder notes, these doublet and triplet regimens are manageable and patients can get through them without any major issues.
 
Infusion reactions to daratumumab-based regimens are possible, but with split dosing this is particularly avoidable. Infusion time is also lessened in that setting with proper pre-dosing. Because of the lack of single-agent activity with elotuzumab (Empliciti), Schroeder adds, there is still ongoing work testing it in combination with other agents.  
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x